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CASE REPORT Open Access
Idiopathic lung fibrosis and anti
myeloperoxidase glomerulonephritis: the
tree that hides the forest
Marc Pineton de Chambrun1, Hilario Nunes2,3, Isabelle Brochériou4,5 and Alexandre Hertig1,5*
Abstract
Background: Although anti-neutrophil cytoplasmic antibodies [ANCA] are frequently found in patients diagnosed
with idiopathic pulmonary fibrosis [IPF], current guidance does not recommend serologic testing for vasculitis.
Case presentation: A 71-year old Caucasian male, diagnosed with IPF three years earlier, presented with rapidly
progressive glomerulonephritis. ANCA were found both in current and historical sera. A kidney biopsy sample was
taken, which revealed a pauci-immune glomerulonephritis, but also areas of glomerular fibrosis, hence strongly
suggesting unrecognized flares of an indolent vasculitis in his past. This made the diagnosis of “idiopathic”
pulmonary fibrosis very unlikely.
Conclusion: As nephrologists, we argue that testing for ANCA should be performed on a systematic basis, at least
in elderly patients, even in the absence of extra-pulmonary signs of vasculitis at presentation.
Keywords: Idiopathic pulmonary fibrosis, Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis
Background
Idiopathic pulmonary fibrosis [IPF] is a progressive fi-
brotic disorder of the lower respiratory tract with in-
creasing incidence rates [1]. By definition, to reach a
diagnosis of IPF other possible causes of interstitial lung
disease, such as domestic or occupational environmental
exposure, drug toxicity, and connective tissue diseases
must be excluded [2]. For the latter, a worldwide consen-
sus was reached recently that a serologic evaluation
should be systematically recommended, particularly for
younger women; this would include testing for rheumatoid
factor and anti-cyclic citrullinated peptide, and carrying
out an antinuclear antibody (titer and pattern) on the basis
of a high benefit/cost ratio [2]. Serologic testing for vascu-
litis is not included in this guidance [2]. Mild pulmonary
hemorrhage may complicate antineutrophil cytoplasmic
antibody [ANCA]-associated vasculitis [AAV] and, more
importantly, it may occasionally go unnoticed. Since fibro-
sis is a non-specific lesion resulting from a perpetuating or
failing repair process that is independent of the cause of
injury, it is reasonable to think that mild pulmonary flares
might cause interstitial lung disease. As a matter of fact,
Japanese and French studies have previously reported that
a non-negligible proportion of patients with IPF were sub-
sequently diagnosed as having AAV. [3–5] Since both IPF
and AAV typically affect elderly adults, and since the cost
of serologic testing for ANCA is relatively low, we believe
that it should be performed even in the absence of any
extra-pulmonary signs of vasculitis at the time of initial
presentation. This could help the differential diagnosis
procedure, and may also increase therapeutic options in a
disease that is all too often rapidly fatal. We take the op-
portunity of a case presentation to review the literature on
this subject and to discuss this opinion.
Case presentation
A 71-year old man, suffering from chronic cough, was
diagnosed with idiopathic lung fibrosis in 2010. He had
a former smoking history of 20 pack years (he stopped
smoking in 2001), but no previous relevant environmen-
tal exposure. Except for bilateral basal crackles, the
physical examination was unremarkable. A computerized
tomography [CT] scan showed reticular opacities,
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honeycombing, and some traction bronchiectasis; fi-
brotic lesions were predominant in the lower parts of
lungs. No ground-glass opacities were found [Fig. 1].
Pulmonary test function was normal, except for the cor-
rected carbon monoxide [CO] diffusing capacity, which
was slightly reduced (60 %). A six-minute walking test
was normal. Cellular analyses of a bronchoalveolar lav-
age [BAL] found 240,000 cells/mm3 consisting of 80 %
macrophages (91 % siderophages), 9 % neutrophils (N <
1 %), and 11 % lymphocytes (N < 10 %). Serum creatin-
ine was within the normal range (0.8 mg/dL), and
hemoglobin concentration was 14.5 g/dL. Urine sedi-
ment was not specifically analyzed, but a urinary dipstick
had found mild microscopic hematuria (1+) and no al-
buminuria. Serum was not screened for ANCA. A final
diagnosis of IPF was made. This patient was lost to
follow-up until 2013, when he presented to the pulmon-
ary ward because of dyspnea on exertion. On that same
day, his serum creatinine was still normal (1 mg/dL). He
was scheduled for lung function tests 4 months later. At
that time, his general condition had deteriorated and he
presented with elevated serum creatinine (6.1 mg/dL)
and acute anemia (9 g/dL versus 13 g/dL 4 months earl-
ier) in the absence of hemoptysis. His uncorrected CO
diffusing capacity was even lower than in 2010 (38 %),
while his corrected CO diffusing capacity had increased
slightly (66 %). A CT-scan showed progression of fibrotic
lesions and again no ground-glass opacities [Fig. 1]. A
urinary dipstick found albuminuria (>3 g/L) and micro-
scopic hematuria (3+). He was then referred to our renal
intensive care unit. Serum fibrinogen was mildly in-
creased (4.76 gr/L), and C3 and C4 were in the normal
range (0.97 and 0.26 gr/L, respectively). A high titer of
anti-myeloperoxidase ANCA was found, and a renal bi-
opsy revealed necrotizing crescentic pauci-immune glom-
erulonephritis [Fig. 2]. Glomerular lesions of different ages
and the coexistence of active necrotizing crescentic lesions
(50 %) and sclerosing segmental or diffuse glomerular le-
sions (33 %) were observed, suggesting unrecognized
flares of glomerulonephritis in the past. The lower cortex
Fig. 1 High-resolution computed tomography scan findings in year 2009 (panels a and b) and 2013 (panels c and d). Both examinations revealed
sub-pleural reticulation, honeycombing, traction bronchiectasis. Lesions predominated in the lower part of the lungs, and had progressed
between 2009 and 2013
Fig. 2 Renal biopsy findings. The glomerulus shows active segmental
necrotizing destructive crescent (asterisk) with destruction of Bowman’s
capsule (arrow). (Periodic Acid Schiff, original magnification x250)
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was infiltrated by mononuclear cells and active tubulitis
was focally observed.
The 2010 serum was retrospectively screened for the
presence of ANCA, which were found at a low level (1:40);
with a perinuclear pattern visible by immunofluorescence.
In contrast to the most recent serum test, neither MPO
nor PR3 specificity was found. Plasmapheresis, methyl-
prednisolone, and cyclophosphamide were promptly ad-
ministered. Renal and pulmonary functions eventually
improved. The serum creatinine, three months post
admission, was 2.4 mg/dL. A maintenance therapy using ri-
tuximab was decided. Eighteen months later, both his renal
and respiratory functions were stable: urinary sediment
was inactive, proteinuria was low (20 mg/mmol creatinine),
serum creatinine was 2.7 mg/dL (estimated glomerular fil-
tration rate 23 ml/min) and his pulmonary forced vital cap-
acity was 2930 mL (76 %). He had not experienced any
other flare, and ANCA remain undetectable, both by im-
munofluorescence and ELISA.
Discussion
In their historic article suggesting that ANCA play a
pathogenic role on AAV, Jennette et al. reported that al-
veolar interstitial fibrosis was frequently observed in pa-
tients with lung manifestations of vasculitis [6]. One
patient in particular is said to have undergone repeated
lung biopsies, the first one showing alveolar capillaritis
alone but the second only interstitial fibrosis [6]. The
retrospective analysis of the case of our patient, includ-
ing his serum tests, makes a diagnosis of occult flares of
alveolar capillaritis and glomerulonephritis rather obvi-
ous. However, the current guidelines regarding the diag-
nosis of IPF state that performing a BAL cellular
analyses in the setting of IPF is at the discretion of the
treating physician and screening for ANCA is not even
discussed [2].
The largest study so far to measure the prevalence of
ANCA in patients with IPF was published by Ando et al.
[7]. At the time of diagnosis 3/61 patients (4.9 %) were
found to have circulating MPO-ANCA, and this rose to
9/61 (14.8 %) during follow up. Two of these 9 patients
went on to develop crescentic glomerulonephritis and,
thus, had a robust final diagnosis of vasculitis. Patients
with MPO-ANCA were more frequently found to have
rheumatoid factor, a lower mean CO diffusing capacity,
and a lower macrophage count on BAL cellular analyses.
Histopathology of 7/9 patients with MPO-ANCA associ-
ated IPF revealed a typical pattern of interstitial pneu-
monia in all cases. This study, as well as that by Hervier
et al. [5] which included 12 such patients, reported an
increased number of eosinophils either in the blood [5] or
in the bronchoalveolar fluid [7]. With respect to patient
outcome, comparing ANCA+ and ANCA- IPF on a pro-
spective basis did not reveal any significant differences [4,
7] and, in particular, survival rates were similar [7]. In line
with this, a retrospective study reported on 53 IPF patients
who were secondarily tested for the presence of proteinase
3 [PR3] and myeloperoxidase [MPO] ANCA. This showed
that 19/53 patients (35.8 %) were positive for ANCA, in-
cluding 17 with MPO and 2 with PR3 specificity. Four pa-
tients out of 19 had a definite diagnosis of
micropolyangitis. There were no major differences in clin-
ical or biological features between ANCA+ and ANCA-
patients, and pulmonary function tests, BAL, and radio-
logical findings all yielded comparable results. As expected
though, immunosuppressive treatment had been more fre-
quently used in the ANCA-positive patients, and a trend
toward a higher rate of improvement was observed in the
ANCA-positive group (83.3 % vs 54.2 %, p = 0.089).
For reasons that are not immediately obvious, the
combination of IPF with AAV is still reported in the lit-
erature as an association of two distinct diseases with
potential pathophysiological links, certainly, but never as
manifestations of one and the same disorder, namely
vasculitis, leading to a fibrosing injury/repair response in
the lung. The lung is frequently involved in micropo-
lyangitis, although mainly through capillaritis and alveo-
lar hemorrhage. ANCA-associated pulmonary fibrosis
typically precedes AAV [8] by several months and some-
times by several years, and so it is argued that a se-
quence of events in which IPF is accompanied by
ANCA, but with no patent alveolar capillaritis, and
which is followed by vasculitis suggests that the ANCA
is not involved in the vasculitis per se, but rather in IPF
via some unknown mechanism(s). First, what are the
odds that a patient will be diagnosed with an idiopathic
disease once he/she has been diagnosed as having sys-
temic vasculitis ? Second, ANCA were first described
decades ago and their pathophysiological role has been
extensively studied, yet we do not know that they have
been involved in any case of isolated abnormal matrix
remodeling without vasculitis, whether in humans or in
animal models. Experimental models have suggested that
ANCA mediate vasculitic lesions via neutrophil activa-
tion, which with different mediators, such as lipopoly-
saccharide and tumor necrosis alpha [9], will harm
tissues. Obviously enough, tissue injury will subsequently
induce the activation of fibroblasts and epithelial cells
and cause fibrosis, but the primum movens here is vas-
culitis, whether patent or occult. Taking into account
the fact that cases of occult flares of vasculitis, whether
in the lung, the kidney or other organs, are known to
occur, and the fact that AAV evolves in flares, we think
that the time has come to include the detection of
ANCA as a reason to prompt further discussion of
chronic and indolent vasculitis in the differential diagno-
sis of a patient presenting with IPF. The prognosis of
this combination is particularly bad [8]. This implies
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testing for ANCA on a systematic basis and, if they are
found to be present, to perform BAL cellular analyses to
look for alveolar hemorrhage and a urinary dipstick to
look for microscopic hematuria. Indeed, non-specific CT
findings and a pattern of usual interstitial pneumonitis
(UIP) without patent signs of alveolar hemorrhage does
not rule out a diagnosis of micropolyangitis.
The PANTHER trial has firmly demonstrated that a
combination of prednisone and azathioprine does not af-
ford any benefit in patients with IPF in general (it was
even shown to increase mortality and acute exacerbation
of the disease) [10]. However, evidence from the litera-
ture is scarce about the real efficacy of immunosuppres-
sive drugs in ANCA-associated pulmonary fibrosis. In
addition, immunosuppressive drugs have potent anti-
inflammatory properties, but do not act on matrix re-
modeling, hence it is counter-intuitive to think that they
would display much efficacy against an inflammatory
disease discovered at a late/fibrotic stage, in contrast
with pirfenidone, for example [11].
Taking all these factors into consideration, we believe
that patients presenting with IPF should be screened for
ANCA, because pulmonary fibrosis could be the end-
result of repeated mild flare(s) of lung vasculitis causing
occult alveolar hemorrhage. In the kidney field, it is
widely accepted that glomerulosclerosis may reflect pre-
vious flares of vasculitis of the glomerular capillary, with
the alveolar capillaries probably sharing the same pattern
of injury/repair response and scarring. The pathophysio-
logical link between indolent vasculitis and fibrogenesis
is the subject of speculation, but local inflammation and
the release of heme proteins into the alveolar chamber
could, for instance, induce oxidative damage and
destabilize lung homeostasis. Two important observa-
tions were made in a recent study assessing the various
histopathological features of AAV with renal involve-
ment : 1) 20.3 % of patients with MPO-AAV were found
to display exclusively chronic/sclerosing lesions at the
renal biopsy and 2) half the patients presented with le-
sions of differing ages, whereas the diagnosis of AAV
was recent (1.6 month in the MPO-AAV group) [12].
For those patients with ANCA associated IPF, we specu-
late that they should be under close scrutiny in order to
capture infra-clinical flares of a vasculitis, and treat them
according to the current guidelines on AAV. In particular,
we recommend that they undergo at least one BAL to de-
tect broncho-alveolar hemorrhage, and urinary dipsticks on
a monthly basis. Microscopic hematuria and protein-
uria are sensitive biomarkers of glomerular injury, and
would rapidly lead to a renal biopsy and correct the
diagnostic. Outside flares, there is no evidence-based
argument to add anti-fibrotic drugs if a diagnosis of
AAV is strongly suspected or even established. It
should also be born in mind that the risk of cancer,
increased by immunosuppressants, could theoretically
be further increased by a stromal depletion [13]. In the
case we present, the use of plasmapheresis at the time
of extracapillary glomerulonephritis, and of rituximab
as maintenance, were decided on the basis of recent
randomized trials (MEPEX [14], and MAINRITSAN
[15], respectively).
Conclusion
In conclusion, we suggest moving from a radiological
and histopathological classification of this disease to a
more molecular and mechanistic approach. A significant
proportion of patients presenting with pulmonary fibro-
sis who test positive for ANCA should be scrutinized
closely and, for them, vasculitis is a disease to look out
for during follow-up. If respiratory or extra-respiratory
signs of vasculitis are found, this would undoubtedly in-
crease therapeutic options in a disease which, at present,
is rapidly fatal.
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